Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

New research on RIG-I
May 2018
SHARING OPTIONS:

SEATTLE—This year’s Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations saw Kineta Immuno-oncology LLC share new data on its RIG-I agonist lead chemical series, which triggers RIG-I-dependent signaling to stimulate chemokine/cytokine production by human PBMCs and stimulates activation of dendritic cells. Small-molecule RIG-I agonists significantly reduced tumor growth in mouse models of colon carcinoma and melanoma. Kineta also presented a new candidate that demonstrated potent innate immune activation and immunogenic cell death (ICD) activities.
 
“These data demonstrate that Kineta’s small-molecule RIG-I agonists activate the innate immune response, induce ICD in tumor cells in vivo and elicit an antitumor memory T cell response controlling tumor growth,” said Kineta CSO Dr. Kristin Bedard. “Demonstrating significant tumor regression in multiple tumor models and selecting additional drug candidates from the lead chemical series are significant advancements for the program.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.